Notice

This is not the latest version of this item. The latest version can be found at: https://scientiasalut.gencat.cat/handle/11351/6527.2

Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorServei Català de la Salut. Gerència del Medicament
dc.date.accessioned2021-11-11T09:45:37Z
dc.date.available2021-11-11T09:45:37Z
dc.date.issued2021-11
dc.identifier.citationServei Català de la Salut. Gerència del Medicament. Medicaments biosimilars. Barcelona: Servei Català de la Salut; 2021.
dc.identifier.urihttps://hdl.handle.net/11351/6527
dc.descriptionBiosimilar drugs; Biological drugs; Usage
dc.description.abstractA drug is considered biological when it contains one or more active ingredients synthesized or derived from a biological source. Its complexity is very variable and can go from proteins already existing in the human body, such as insulin or growth hormone, to biotechnological drugs designed using molecular biology techniques with genetic manipulation (monoclonal antibodies, gene therapy, among others)
dc.language.isocat
dc.publisherServei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMedicaments - Equivalència terapèutica
dc.subjectBiotecnologia farmacèutica
dc.subject.meshBiosimilar Pharmaceuticals
dc.subject.mesh/administration & dosage
dc.titleMedicaments biosimilars
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsfármacos biosimilares
dc.subject.decs/administración & dosificación
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

VersionItemDateSummary

*Selected version